- Kymera Therapeutics Inc (NASDAQ:KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers.
- KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.
- No treatment-related adverse events have been observed to date.
- Also, the FDA has lifted the partial clinical hold on the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474. Kymera plans to initiate repeat dosing in July 2021.
- A subsequent cohort in the Phase 1 trial will include up to 20 patients with atopic dermatitis and hidradenitis suppurativa.
- Kymera expects to present updated results from the healthy volunteer SAD and MAD portions of the trial in Q4 of 2021.
- Kymera will host a conference call and webcast today at 8:00 a.m. ET.
- Price Action: KYMR shares are up 8.16% at $48 in the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
